STOCK TITAN

Oscar Health appoints Cohen, Larsen and Taneja directors

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Oscar Health, Inc. appointed Tomer Cohen, Eric Larsen and Rajat Taneja as directors, effective November 13, 2026, increasing the board from eight to eleven members. Their terms run through the 2027 annual meeting and until successors are elected and qualified or earlier termination. Cohen joins the Talent and Compensation Committee; Taneja joins the Audit and Nominating and Corporate Governance committees. The board determined all three qualify as independent under New York Stock Exchange rules.

Each is eligible for a $70,000 annual board retainer, plus applicable committee retainers, and initial and annual restricted stock unit grants valued at $200,000 each. The grants vest in full on the earlier of one year after grant or the next annual meeting, subject to continued service. Oscar Health also expects each director to enter its standard indemnification agreement.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Board size 8 to 11 directors After the appointments effective November 13, 2026
Annual board retainer $70,000 Per non-employee director
Audit Committee retainer $10,000 Annual cash retainer, if applicable
Compensation Committee retainer $7,500 Annual cash retainer, if applicable
Nominating and Corporate Governance Committee retainer $5,000 Annual cash retainer, if applicable
Initial restricted stock unit grant $200,000 Value per director, subject to proration
Annual restricted stock unit grant $200,000 Value per director
Director appointments effective date November 13, 2026 Cohen, Larsen and Taneja
restricted stock units financial
"initial grant of restricted stock units (RSUs)"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
vesting financial
"which vests in full on the earlier to occur"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
indemnification agreement technical
"standard indemnification agreement for directors and officers"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much cash and equity compensation are Oscar Health's new directors eligible for?

Each director is eligible for a $70,000 annual board retainer, plus applicable annual committee retainers of $10,000 for Audit, $7,500 for Compensation and $5,000 for Nominating and Corporate Governance service. Each is also eligible for initial and annual restricted stock unit grants valued at $200,000 each.

When do Oscar Health's new directors' restricted stock units vest?

The initial and annual grants vest in full on the earlier of the one-year anniversary of the grant date or the date of the next annual meeting after the grant date, subject to the director's continued service through the applicable vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001568651FALSE00015686512026-11-122026-11-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 12, 2026
Oscar Health, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware001-4015446-1315570
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)

75 Varick Street, 5th Floor
New York, New York 10013
(Address of Principal Executive Offices) (Zip Code)
(646) 403-3677
(Registrant’s telephone number, including area code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbols
Name of each exchange
on which registered
Class A Common Stock, $0.00001 par value per shareOSCRNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 12, 2026, the Board of Directors (the “Board”) of Oscar Health, Inc. (the “Company”) appointed Messrs. Tomer Cohen, Eric Larsen, and Rajat Taneja to the Board, effective November 13, 2026 (the “Effective Date”), and increased the size of the Board from eight to eleven directors in connection therewith. Each director will serve for a term expiring at the Company’s annual meeting of stockholders to be held in 2027 and until his successor is duly elected and qualified or until his earlier death, disqualification, resignation or removal. Mr. Cohen was also appointed as a member of the Talent and Compensation Committee of the Board (the “Compensation Committee”), and Mr. Taneja was appointed as a member of the Audit Committee and the Nominating and Corporate Governance Committee (the “NCG Committee”), in each case effective as of the Effective Date. The Board determined that each of Messrs. Cohen, Larsen, and Taneja qualifies as independent under the rules of the New York Stock Exchange, including, in Mr. Cohen’s case, with respect to service on the Compensation Committee, and in Mr. Taneja’s case, with respect to service on the Audit Committee.

Mr. Cohen is a technology and product leader with a track record of building consumer experiences across startups and established companies. He served as LinkedIn Corporation’s Senior Vice President and Chief Product Officer from 2020 to 2026, and subsequently as an Executive Advisor. In his role as Senior Vice President and Chief Product Officer, Mr. Cohen set the company’s product strategy, oversaw product development, user experience design, business development, content creation, and customer operations, and advanced AI across the organization. From 2012 to 2020, he also served in various key leadership roles at LinkedIn, helping launch and scale new innovative member and customer experiences. Prior to LinkedIn, Mr. Cohen worked as an entrepreneur with Greylock Partners and founded a company in the personal CRM space. He teaches AI for product and business leaders at Stanford Graduate School of Business and serves on the board of Gusto. Mr. Cohen holds a B.S. from Ben-Gurion University of the Negev and an M.B.A. from Stanford University.

Mr. Larsen brings decades of leadership across healthcare, private equity, and venture capital, with a forward-looking perspective on frontier AI. He serves as President of TowerBrook Advisors and as a member of TowerBrook Capital Partners healthcare leadership team, having held these roles since 2023. Mr. Larsen previously served as President of The Advisory Board Company, L.P. from 2019 to 2023 and subsequently as President Emeritus. He is also a senior advisor to Thrive Capital, Oscar Health’s majority stockholder, and serves on the boards of R1 RCM, eMed Population Health, Thrive Global, and as Chairman of the Washington National Opera. Mr. Larsen holds a B.S. in Foreign Service from Georgetown University.

Mr. Taneja is a seasoned technology executive with extensive experience building secure technology platforms at global scale. He has served as President of Technology at Visa, Inc., leading global technology research, product development, cybersecurity, operations and infrastructure, and technology innovation and investment strategy since 2019. Mr. Taneja was previously Executive Vice President of Technology and Operations at Visa from 2013 to 2019, Executive Vice President and Chief Technology Officer of Electronic Arts, Inc. from 2011 to 2013, and held senior leadership roles at Microsoft Corporation. He serves on the board of MSCI Inc., where he chairs the Technology and Data Committee and serves on the Audit and Risk Committee. Mr. Taneja holds a B.E. from Jadavpur University and an M.B.A. from Washington State University.

In connection with their service as non-employee directors, Messrs. Cohen, Larsen, and Taneja are each eligible to receive compensation consistent with the Company’s Non-Employee Director Compensation Program, which provides for: (i) an annual cash retainer of, as applicable, (a) $70,000 for serving on the Board, (b) $10,000 for serving as a member of the Audit Committee, (c) $7,500 for serving as a member of the Compensation Committee, (d) $5,000 for serving as a member of the NCG Committee, each of which will be paid in quarterly installments in arrears and will be prorated for any partial calendar quarter of service; (ii) an initial grant of restricted stock units (“RSUs”) equal in value to $200,000 (subject to proration), as measured by the closing price of the Company’s Class A common stock, par value $0.00001 per share (“Class A common stock”) on the grant date, which vests in full on the earlier to occur of (a) the one-year anniversary of the applicable grant date and (b) the date of the next annual meeting of stockholders following the grant date, subject to such director’s continued service through the applicable vesting date; and (iii) an annual grant, on the date of the Company’s annual meeting of stockholders, of RSUs equal



in value to $200,000, as measured by the closing price of the Class A common stock on the grant date, and that vests in full on the earlier to occur of (a) the one-year anniversary of the applicable grant date and (b) the date of the next annual meeting of stockholders following the grant date, subject to such director’s continued service through the applicable vesting date.

The Company also expects each of Messrs. Cohen, Larsen, and Taneja to enter into the Company’s standard indemnification agreement for directors and officers.







SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Oscar Health, Inc.
Date: November 16, 2026By:/s/ Adam McAnaney
Name:Adam McAnaney
Title:Chief Legal Officer


Filing Exhibits & Attachments

3 documents

Keep reading